Prostate Cancer Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Tumor Biomarker Tests,Imaging,Biopsy,Other), By Application (Age Below 55,Age 55-75,Age Above 75), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

PROSTATE CANCER DIAGNOSTICS MARKET OVERVIEW

Global Prostate Cancer Diagnostics market size is anticipated to be worth USD 16.48 billion in 2026 and is expected to reach USD 33.20 billion by 2035 at a CAGR of 8.1%.

The Prostate Cancer Diagnostics Market is expanding due to the rising incidence of prostate cancer and increased adoption of early detection technologies across hospitals, diagnostic laboratories, and research centers. Globally, prostate cancer represents approximately 15% of all cancers diagnosed in men, with more than 1.4 million new cases recorded annually. Diagnostic procedures include prostate-specific antigen (PSA) tests, imaging scans, molecular tests, and biopsy procedures, with PSA screening performed in nearly 60% of men above 50 years in developed healthcare systems. Over 65% of prostate cancer diagnoses occur in men aged 65 years or older, which significantly increases demand for diagnostic tools. Additionally, over 35% of newly diagnosed cases are detected through biomarker-based screening programs, strengthening the expansion of the Prostate Cancer Diagnostics Market Analysis and Prostate Cancer Diagnostics Industry Report landscape.

The United States dominates diagnostic adoption, accounting for nearly 32% of global prostate cancer screening procedures conducted annually. More than 288,000 new prostate cancer cases were diagnosed in the U.S. in 2023, representing about 27% of cancers diagnosed among American men. PSA testing remains the most widely used screening method, with approximately 70% of men aged 55–69 undergoing at least one PSA test. Around 1 million prostate biopsies are performed annually in the U.S., and MRI-guided biopsy techniques account for nearly 28% of procedures. In addition, over 5,000 certified diagnostic laboratories conduct prostate cancer testing nationwide, strengthening the Prostate Cancer Diagnostics Market Outlook and Prostate Cancer Diagnostics Market Insights across the U.S. healthcare system.

KEY FINDINGS OF PROSTATE CANCER DIAGNOSTICS MARKET

• Key Market Driver: Approximately 68% of prostate cancer cases are diagnosed through early screening programs, while PSA testing participation increased by 22% among men aged 50–70, and nearly 54% of hospitals now utilize biomarker-based diagnostic platforms to improve early-stage detection rates.

• Major Market Restraint: Nearly 36% of PSA screening results lead to false positives, while 21% of patients undergo unnecessary biopsies, and about 18% of diagnostic tests face clinical accuracy limitations, reducing physician confidence in early screening procedures.

• Emerging Trends: Around 41% of diagnostic laboratories are integrating genomic testing, while 33% of hospitals have adopted MRI-guided biopsy systems, and nearly 29% of diagnostic centers now offer AI-assisted imaging tools for prostate cancer screening.

• Regional Leadership: North America holds approximately 39% of global diagnostic procedures, followed by Europe with 28%, Asia-Pacific with 23%, and Middle East & Africa accounting for nearly 10% of prostate cancer diagnostics testing activity.

• Competitive Landscape: The top 10 diagnostic companies control nearly 62% of the market, while the leading 2 companies account for around 24% of global diagnostic test deployment, and over 150 regional diagnostic firms contribute about 38% of industry testing capacity.

• Market Segmentation: Tumor biomarker tests represent approximately 34% of diagnostic procedures, imaging accounts for 27%, biopsy contributes 31%, and other diagnostic technologies make up nearly 8% of global prostate cancer diagnostic testing.

• Recent Development: Between 2023 and 2025, more than 42 new molecular diagnostic tests were introduced, while 19 advanced imaging systems were approved for prostate cancer detection, and over 26 diagnostic partnerships were established globally.

LATEST TRENDS

The Prostate Cancer Diagnostics Market Trends are increasingly driven by technological advancements in molecular diagnostics, imaging systems, and precision medicine technologies. More than 1.4 million new prostate cancer cases are diagnosed annually worldwide, with approximately 375,000 deaths recorded each year, making prostate cancer the second most common cancer among men globally. Diagnostic laboratories are increasingly adopting next-generation sequencing technologies, with over 30% of oncology diagnostic labs integrating genomic testing panels for prostate cancer risk identification. Another key Prostate Cancer Diagnostics Market Trend is the rising adoption of multiparametric MRI (mpMRI) for early detection. Studies indicate that mpMRI improves detection accuracy by nearly 25% compared with traditional biopsy techniques. In several developed healthcare systems, nearly 40% of suspected prostate cancer cases now undergo MRI before biopsy procedures, improving diagnostic precision and reducing unnecessary procedures.

Additionally, the use of liquid biopsy technologies has increased significantly in the Prostate Cancer Diagnostics Industry Analysis. Around 18% of oncology diagnostic laboratories globally have implemented circulating tumor DNA testing platforms, enabling non-invasive cancer detection. Artificial intelligence is also influencing diagnostic workflows, with approximately 22% of imaging centers implementing AI-assisted radiology software to analyze prostate MRI scans. Growing screening awareness campaigns have increased screening participation rates by nearly 17% in men aged 50–65 over the past five years, supporting the expansion of the Prostate Cancer Diagnostics Market Research Report landscape and increasing adoption across healthcare systems worldwide.

MARKET DYNAMICS

Driver

Rising prevalence of prostate cancer worldwide

The increasing prevalence of prostate cancer remains the primary driver of the Prostate Cancer Diagnostics Market Growth. Globally, more than 1.4 million men are diagnosed with prostate cancer every year, accounting for nearly 7% of all cancer-related deaths among men. In aging populations, particularly in developed economies, prostate cancer incidence rises significantly, with nearly 60% of cases diagnosed in men older than 65 years. Screening programs across developed healthcare systems have increased testing rates, with PSA screening adoption reaching nearly 65% among men aged 55–69 in developed countries. Additionally, healthcare providers perform more than 2 million prostate biopsies annually worldwide, highlighting the expanding diagnostic demand. Increased government health programs and cancer awareness initiatives have also contributed to screening participation increases of approximately 15% in several regions, strengthening the Prostate Cancer Diagnostics Market Forecast.

Restraint

Limitations in screening accuracy and overdiagnosis

Despite technological advancements, diagnostic limitations remain a challenge in the Prostate Cancer Diagnostics Market Analysis. PSA testing, which is the most commonly used screening method, produces false positive rates ranging from 20% to 35%, leading to unnecessary diagnostic procedures. Nearly 25% of prostate biopsies performed globally return negative results, despite elevated PSA levels. Additionally, overdiagnosis is estimated to occur in approximately 30% of detected prostate cancer cases, where tumors may not progress aggressively during a patient's lifetime. These diagnostic inaccuracies increase healthcare costs and can expose patients to unnecessary medical interventions. Clinical studies indicate that around 18% of prostate biopsy procedures result in complications such as infection or bleeding, further raising concerns about diagnostic reliability and safety in the Prostate Cancer Diagnostics Industry Report.

Expansion of genomic and biomarker testing

Opportunity

The increasing adoption of genomic profiling technologies represents a major opportunity in the Prostate Cancer Diagnostics Market Opportunities landscape. Molecular diagnostic tools, including gene expression profiling and genomic risk scoring tests, are now used in nearly 28% of prostate cancer diagnostic pathways. Genomic biomarker tests such as multi-gene panels can improve risk stratification accuracy by nearly 35% compared with traditional PSA testing alone. Precision medicine initiatives across healthcare systems have accelerated investment in molecular diagnostics, with more than 70 oncology research programs currently investigating genomic biomarkers for prostate cancer detection.

Additionally, clinical trials involving over 12,000 patients worldwide are evaluating new biomarker-based screening methods. These advancements support the expansion of personalized diagnostic strategies and significantly improve clinical decision-making in the Prostate Cancer Diagnostics Market Outlook.

High cost of advanced diagnostic technologies

Challenge

The cost of advanced diagnostic technologies remains a challenge in the Prostate Cancer Diagnostics Industry Analysis. Multiparametric MRI scans, genomic biomarker tests, and advanced imaging procedures require specialized equipment and trained professionals, increasing healthcare system expenditure. MRI-based prostate diagnostic procedures can cost 2 to 3 times more than traditional ultrasound-based biopsies, limiting accessibility in emerging economies.

Additionally, nearly 45% of hospitals in low-income regions lack access to advanced MRI systems, restricting adoption of modern diagnostic tools. Genomic testing platforms also require specialized laboratory infrastructure, with installation costs exceeding standard diagnostic laboratory equipment by nearly 40%. These financial and infrastructure barriers limit the widespread availability of advanced prostate cancer diagnostic services across developing healthcare markets.

•   
•   
  

  Download Free Sample to learn more about this report

    

PROSTATE CANCER DIAGNOSTICS MARKET SEGMENTATION

By Type

• Tumor Biomarker Tests: Tumor biomarker testing represents nearly 34% of diagnostic procedures in the Prostate Cancer Diagnostics Market. PSA testing remains the most widely used biomarker screening method, with approximately 45 million PSA tests conducted annually worldwide. New genomic biomarker tests, including multi-gene expression panels, are used in nearly 12% of diagnostic pathways, improving early detection accuracy. Biomarker-based diagnostics can increase early-stage cancer detection rates by nearly 30%, particularly in patients with intermediate PSA levels. Approximately 18% of diagnostic laboratories globally now offer advanced genomic prostate cancer testing services, strengthening the Prostate Cancer Diagnostics Market Insights.

• Imaging: Imaging technologies account for approximately 27% of prostate cancer diagnostic procedures worldwide. Multiparametric MRI has become a critical diagnostic tool, with nearly 40% of prostate cancer screening programs incorporating MRI scans prior to biopsy. MRI-guided diagnostic methods improve cancer detection accuracy by nearly 25% compared with ultrasound-only approaches. Additionally, over 15,000 MRI scanners globally are used in oncology diagnostics, and approximately 22% of imaging centers utilize AI-assisted radiology tools for prostate cancer detection.

• Biopsy: Biopsy procedures represent nearly 31% of prostate cancer diagnostic confirmation methods worldwide. Approximately 2 million prostate biopsies are performed annually, with transrectal ultrasound-guided biopsy accounting for nearly 72% of procedures. MRI-targeted biopsies represent about 28% of procedures, providing improved detection accuracy for aggressive tumors. Biopsy analysis enables confirmation of cancer grading using the Gleason scoring system, which categorizes tumor aggressiveness into 5 distinct grade groups used for treatment planning.

• Other: Other diagnostic methods represent approximately 8% of the Prostate Cancer Diagnostics Market Share. These include urine-based biomarker tests, circulating tumor DNA assays, and emerging liquid biopsy technologies. Urine biomarker testing is used in approximately 6% of prostate cancer diagnostic workflows, providing non-invasive screening options. Liquid biopsy testing is currently used in around 3% of advanced oncology diagnostic laboratories, but ongoing clinical trials involving more than 9,000 patients are evaluating its future diagnostic potential.

By Application

• Age Below 55: Men aged below 55 years account for approximately 18% of prostate cancer diagnostic testing globally. Screening in this age group is typically recommended for individuals with genetic risk factors or family history. Approximately 12% of prostate cancer cases are diagnosed in men younger than 55, while hereditary genetic mutations contribute to nearly 5–10% of cases. Early detection in this demographic relies heavily on genomic testing and PSA monitoring.

• Age 55-75: The 55–75 age group represents nearly 58% of prostate cancer diagnostic procedures worldwide, making it the largest application segment in the Prostate Cancer Diagnostics Market Forecast. Clinical data indicate that nearly 65% of prostate cancer diagnoses occur within this age range, and screening programs target men beginning at age 55. PSA testing participation rates reach approximately 70% in men aged 55–69, contributing significantly to diagnostic demand.

• Age Above 75: Men aged above 75 years account for approximately 24% of diagnostic procedures globally. Although screening guidelines vary, approximately 28% of prostate cancer deaths occur in this age group, highlighting the importance of continued diagnostic monitoring. Many healthcare providers perform targeted diagnostic testing based on symptom progression rather than routine screening in elderly populations.

•   
•   
  Download Free Sample to learn more about this report

    

PROSTATE CANCER DIAGNOSTICS MARKET REGIONAL OUTLOOK

• North America

North America leads the Prostate Cancer Diagnostics Market Share with approximately 39% of global diagnostic procedures. The United States accounts for the majority of regional testing, with nearly 288,000 prostate cancer cases diagnosed annually. Screening participation rates exceed 65% among men aged 55–69, supported by extensive healthcare infrastructure and advanced diagnostic laboratories. More than 7,000 oncology diagnostic centers operate across North America, providing PSA testing, genomic screening, and imaging diagnostics. Multiparametric MRI adoption is particularly strong in the region, with nearly 45% of prostate cancer diagnostic pathways including MRI imaging prior to biopsy. The United States performs approximately 1 million prostate biopsies each year, while Canada reports nearly 24,000 new prostate cancer cases annually. Government cancer screening initiatives and strong healthcare spending continue to expand diagnostic access across the region.

• Europe

Europe represents approximately 28% of global prostate cancer diagnostic activity. More than 470,000 new prostate cancer cases are diagnosed annually across European countries, with higher prevalence observed in Western Europe. Screening participation rates vary between 40% and 65% depending on national healthcare programs. Countries such as Germany, the United Kingdom, France, and Italy collectively account for more than 60% of European diagnostic testing. Approximately 30% of European hospitals have implemented genomic biomarker testing, while multiparametric MRI usage exceeds 35% in advanced healthcare systems. The region also operates more than 4,500 oncology diagnostic laboratories, supporting increasing prostate cancer screening programs.

• Asia-Pacific

Asia-Pacific accounts for approximately 23% of global prostate cancer diagnostic testing, with rapidly expanding healthcare infrastructure. The region records more than 300,000 new prostate cancer cases annually, with incidence rates rising due to aging populations. Japan, China, South Korea, and Australia represent the largest diagnostic markets in the region. Japan reports nearly 95,000 prostate cancer diagnoses annually, while China records over 120,000 cases each year. Screening awareness campaigns have increased PSA testing participation by nearly 20% in urban healthcare systems. Additionally, more than 2,500 diagnostic laboratories in Asia-Pacific now offer advanced prostate cancer testing services, supporting the Prostate Cancer Diagnostics Market Growth across the region.

• Middle East & Africa

The Middle East & Africa account for approximately 10% of global prostate cancer diagnostic testing. The region records nearly 85,000 new prostate cancer cases annually, with screening rates lower than other regions due to limited diagnostic infrastructure. Countries such as Saudi Arabia, South Africa, and the United Arab Emirates represent the largest diagnostic markets. Approximately 35% of tertiary hospitals in the region provide PSA screening services, while only 18% of hospitals offer advanced MRI-based prostate cancer diagnostics. Healthcare investment programs are expanding diagnostic capacity, with more than 120 new oncology diagnostic centers established in the region over the past five years.

LIST OF TOP PROSTATE CANCER DIAGNOSTICS COMPANIES

• OPKO
• Genomic Health
• Abbott
• Beckman Coulter
• Siemens Healthcare
• bioMeriux
• Roche
• MDx Health
• DiaSorin
• Myriad Genetics
• Ambry Genetics

Top Two Companies By Market Share

• Roche holds approximately 14% of global prostate cancer diagnostic testing platforms, with more than 30,000 diagnostic systems installed worldwide and over 100 million diagnostic tests performed annually.
• Abbott accounts for nearly 10% of global diagnostic testing capacity, operating more than 20 manufacturing and diagnostic research facilities and supplying testing platforms to over 160 countries worldwide.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the Prostate Cancer Diagnostics Market continues to increase due to rising prostate cancer incidence and expanding diagnostic technologies. Globally, more than 120 clinical trials are currently investigating advanced prostate cancer diagnostic technologies, including genomic biomarkers, liquid biopsy platforms, and AI-assisted imaging systems. Venture capital investment in oncology diagnostics has supported more than 70 startup companies developing molecular diagnostic technologies. Healthcare institutions worldwide are increasing diagnostic infrastructure capacity, with over 3,500 new oncology diagnostic laboratories established globally between 2018 and 2024. Government funding programs have also expanded prostate cancer research, supporting more than 200 academic research projects focused on biomarker discovery and early detection technologies.

Additionally, pharmaceutical and diagnostic companies are investing in personalized medicine solutions, with nearly 45% of oncology research programs focusing on precision diagnostic technologies. These investments strengthen the Prostate Cancer Diagnostics Market Opportunities by improving early detection accuracy and expanding screening accessibility worldwide.

NEW PRODUCT DEVELOPMENT

New product development in the Prostate Cancer Diagnostics Market is focused on improving diagnostic accuracy, reducing invasive procedures, and enabling personalized cancer detection. More than 40 new molecular diagnostic tests have been introduced globally between 2022 and 2025, targeting genomic biomarkers associated with prostate cancer risk. Liquid biopsy technologies are emerging as a major innovation area. Approximately 15 new circulating tumor DNA diagnostic platforms have entered clinical testing stages, allowing non-invasive detection of prostate cancer biomarkers in blood samples. Early clinical studies involving more than 6,000 patients have shown detection accuracy improvements of nearly 28% compared with conventional PSA screening methods.

Imaging technologies are also evolving rapidly. Several medical device manufacturers have introduced AI-enabled MRI diagnostic software, capable of analyzing more than 200 imaging parameters during prostate scans. Additionally, automated pathology platforms now process over 1,000 biopsy tissue samples per day in high-volume diagnostic laboratories, improving workflow efficiency. These technological advancements are significantly improving diagnostic capabilities and supporting innovation across the Prostate Cancer Diagnostics Market Research Report landscape.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2024, Roche expanded its molecular diagnostic platform with new genomic testing panels capable of analyzing more than 50 prostate cancer biomarkers simultaneously.
• In 2023, Abbott introduced an advanced immunoassay diagnostic system capable of processing over 400 PSA tests per hour in high-volume diagnostic laboratories.
• In 2024, Myriad Genetics launched an updated genomic risk assessment test validated using clinical data from over 10,000 prostate cancer patients.
• In 2025, Siemens Healthcare introduced AI-enabled prostate MRI software capable of analyzing over 200 imaging variables within 5 minutes.
• In 2023, MDx Health expanded its prostate cancer molecular diagnostic testing program across more than 3,500 urology clinics worldwide.

PROSTATE CANCER DIAGNOSTICS MARKET REPORT COVERAGE

The Prostate Cancer Diagnostics Market Report provides a comprehensive analysis of diagnostic technologies, screening programs, and healthcare infrastructure supporting prostate cancer detection worldwide. The report evaluates more than 20 diagnostic technologies, including PSA testing, genomic biomarker assays, MRI imaging systems, and biopsy procedures used in prostate cancer detection. The study analyzes diagnostic trends across over 40 countries, covering screening participation rates, healthcare infrastructure capacity, and diagnostic technology adoption levels. Additionally, the report evaluates more than 50 diagnostic companies involved in the development of prostate cancer testing technologies.

The Prostate Cancer Diagnostics Market Research Report also examines demographic trends, highlighting that nearly 65% of prostate cancer cases occur in men aged above 65, while screening programs target more than 300 million men globally. Furthermore, the report reviews clinical research data from over 120 ongoing diagnostic trials, providing insights into emerging technologies such as liquid biopsy testing, genomic risk scoring systems, and AI-assisted imaging platforms. The coverage includes market segmentation by diagnostic technology and patient age groups, regional healthcare infrastructure analysis, and evaluation of emerging diagnostic innovations shaping the Prostate Cancer Diagnostics Market Outlook and Prostate Cancer Diagnostics Market Insights globally.